| 4.38 -0.11 (-2.45%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.44  |
1-year : | 7.52 |
| Resists | First : | 5.51 |
Second : | 6.44 |
| Pivot price | 4.82  |
|||
| Supports | First : | 4.03 |
Second : | 3.35 |
| MAs | MA(5) : | 4.47 |
MA(20) : | 5 |
| MA(100) : | 4.45 |
MA(250) : | 4.68 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 8.2 |
D(3) : | 5.6 |
| RSI | RSI(14): 41.3 |
|||
| 52-week | High : | 7.73 | Low : | 2.9 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALT ] has closed above bottom band by 22.1%. Bollinger Bands are 28.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.5 - 4.53 | 4.53 - 4.55 |
| Low: | 4.28 - 4.32 | 4.32 - 4.35 |
| Close: | 4.33 - 4.38 | 4.38 - 4.42 |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Tue, 17 Feb 2026
Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances - Yahoo Finance
Tue, 03 Feb 2026
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 (NASDAQ:ALT) - Seeking Alpha
Mon, 02 Feb 2026
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development - Yahoo Finance
Wed, 28 Jan 2026
Altimmune: Why Breakthrough Status Isn't A 'Buy' Signal Just Yet (NASDAQ:ALT) - Seeking Alpha
Wed, 28 Jan 2026
Altimmune (ALT) Shares Slide On $75 Million Stock Offering - Sahm
Thu, 22 Jan 2026
Altimmune (ALT) Receives FDA Breakthrough Therapy Designation, Shares Rise Nearly 4% - Intellectia AI
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 125 (M) |
| Held by Insiders | 1.0351e+008 (%) |
| Held by Institutions | 0.6 (%) |
| Shares Short | 23,720 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.034e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -417 % |
| Return on Assets (ttm) | 179.9 % |
| Return on Equity (ttm) | -30.9 % |
| Qtrly Rev. Growth | 20000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -1753.67 |
| EBITDA (p.s.) | -2.25933e+009 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -66 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.06 |
| Dividend | 0 |
| Forward Dividend | 2.641e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|